Finch Therapeutics Group, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew Blischak
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 75 State Street Boston MA United States of America 02109
- IPO Date
- Mar 18, 2021
- CIK
- 0001733257
- Website
- finchtherapeutics.com
- Similar Companies
- Business
- Finch Therapeutics Group, Inc. engages in the discovery, development, and commercialization of microbiome-based therapeutics designed to restore and modulate human gut microbiota to treat or prevent disease. Main products and services - Microbiome therapeutics pipeline development; platform-enabled discovery and engineering of live biotherapeutic products (LBPs) targeting immune-mediated and metabolic diseases - Preclinical research services; translational science capabilities including microbiome profiling, metagenomics, and systems biology analyses - Clinical development programs; Phase I/II/III clinical trial execution support for microbiome-based therapies - Manufacturing and regulatory support; process development and GMP manufacturing capabilities for LBPs; regulatory strategy and interactions with health authorities - Companion diagnostics and biomarker strategies; patient stratification and pharmacodynamic/response biomarkers aligned with microbiome interventions - Data analytics and bioinformatics services; integrative analytics to link microbial composition, metabolites, and clinical outcomes - Strategic collaboration services; research partnerships, licensing, and co-development arrangements with biopharma, academia, and contract research organizations Latest major company changes - Strategic partnerships and alliances in microbiome research and development, expanding collaborative programs with pharmaceutical and biotech partners to advance candidate LBPs through clinical development - Funding and capitalization rounds to bolster pipeline and platform capabilities, with ongoing corporate financing activities to support GMP manufacturing scale-up and regulatory submissions - Introduction of new product candidates and enhanced platform capabilities for immune-mediated and metabolic indications, including pipeline expansions and priority programs - Corporate restructurings and operational realignments aimed at optimizing development timelines, manufacturing readiness, and regulatory pathways - Updates to corporate branding or organizational structure reflecting refocusing of business segments and integration of subsidiary entities under a unified strategic framework - Significant operational changes within the last 1-2 years, including expansions in manufacturing capacity, further delineation of product development milestones, and enhanced global clinical trial execution capabilities Additional context - Industry and segments: biotechnology; microbiome therapeutics; live biotherapeutic products; clinical development services; synthetic biology and microbiome analytics - Target markets and customers: biopharmaceutical companies, academic collaborators, contract research organizations, and eventually healthcare providers and patients through approved products - Geographic operations: primary activities in the United States with potential collaborations and development efforts across North America and Europe; manufacturing and regulatory engagements span multiple regions to support global trials - Founding year and headquarters: founded in the 2010s; headquarters located in the United States - Subsidiaries and parent relationships: operates as a standalone biotechnology company with potential subsidiary entities or affiliates supporting R&D, manufacturing, or regional strategic activities - Regulatory and commercial context: focused on advancing microbiome-based therapies through clinical development with attention to FDA and global regulatory guidance, aiming for later-stage partnerships or product approvals depending on program advancement
Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.7% – Here’s What Happened
Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)
Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
Financial Survey: ZIVO Bioscience (NASDAQ:ZIVO) versus Finch Therapeutics Group (NASDAQ:FNCH)
Arquitos Capital's Largest Holdings For Q1 2025
Finch Announces Delisting from Nasdaq and SEC Deregistration
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
Why Finch Therapeutics Stock Is Skyrocketing Today
Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
Best Penny Stocks to Buy Today? 3 to Watch on April 29th
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes